Detection of Minimal Residual Disease Post-prostatectomy
Sponsored by Radboud University Medical Center
About this trial
Last updated 3 months ago
Study ID
2025-18163
Status
Recruiting
Type
Observational
Placebo
No
Accepting
18+ Years
Male
Trial Timing
Started 7 months ago
What is this trial about?
The clinical objective for this pilot study is to determine whether minimal residual disease (MRD) detection in high-risk prostate cancer, utilizing a custom-made prostate-specific circulating tumor DNA (ctDNA) panel, may lead to more optimal prediction of disease recurrence following radical prostatectomy.
What are the participation requirements?
Inclusion Criteria
* Male aged 18 years or older;
* High-risk prostate cancer, defined as:
1. High-risk localized prostate cancer, with PSA level >20 ng/mL, Gleason score 8-10 (ISUP grade 4/5) at prostate biopsies, or iT3a (based on multi-parametric MRI of the prostate); or
2. High-risk locally advanced prostate cancer, having any PSA level, any Gleason score/ISUP grade, iT3b-4 (based on multi-parametric MRI of the prostate) or iN1 (based on PSMA PET/CT imaging);
* Scheduled for robot-assisted radical prostatectomy;
* Willingness to consent to both patient information sheets regarding tissue and liquid biobanking.
Exclusion Criteria
* Relevant contra-indications that may limit clinical follow-up or blood collection, as assessed by the including physician.